News | October 09, 2024
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Revolutionary technology will further boost OneSource’s scientific services offerings
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Subscribe To Our Newsletter & Stay Updated
